1600-6143/asset/olbannerleft.gif?v=1&s=c46a3f174bfd9c6eb548cc809401524372c32e90)
1600-6143/asset/olbannerright.gif?v=1&s=9fc9790fa8ad5ef85aeaf408bf0d3d969d2fc012)
You have full text access to this OnlineOpen article
Human Papillomavirus Infection in Solid Organ Transplant Recipients
Article first published online: 16 DEC 2009
DOI: 10.1111/j.1600-6143.2009.02906.x
© 2009 The Authors Journal compilation © 2009 The American Society of Transplantation and the American Society of Transplant Surgeons
Issue
American Journal of Transplantation
Special Issue: AST Infectious Diseases Guidelines 2nd Edition
Volume 9, Issue Supplement s4, pages S151–S160, December 2009
Additional Information
How to Cite
Kwak, E. J., Julian, K. and the AST Infectious Diseases Community of Practice (2009), Human Papillomavirus Infection in Solid Organ Transplant Recipients. American Journal of Transplantation, 9: S151–S160. doi: 10.1111/j.1600-6143.2009.02906.x
Publication History
- Issue published online: 16 DEC 2009
- Article first published online: 16 DEC 2009
References
- 1, . The spectrum and clinical sequelae of human papillomavirus infection. Gynecol Oncol 2007; 107(2 Suppl 1): S6–S13.
- 2, , et al. External anogenital lesions in organ transplant recipients. A clinicopathologic and virologic assessment. Arch Dermatol 1997; 133: 175–178.
- 3, , , , . Skin diseases in children with organ transplants. J Am Acad Dermatol 2001; 44: 932–939.
- 4. Cancers of the anogenital region in renal transplant recipients. Analysis of 65 cases. Cancer 1986; 58: 611–616.
- 5, , et al. Human papilloma virus infection and cervical intraepithelial neoplasia in transplanted patients. Transplant Proc 2008; 40: 1877–1880.
- 6, , . Benign human papillomavirus infection in renal transplant recipients. Int J Dermatol 1991; 30: 785–789.
- 7, , , , . Cancer, warts, and sunshine in renal transplant patients. Lancet 1984; 1: 702–705.
- 8, . Papillomaviruses. In: MandellGL, BennettJE, DolinR, eds. Principles and Practice of Infectious Diseases, 6th Ed. Philadelphia , Churchill Livingstone, 2006: 1841–1856.
- 9, , et al. External anogenital lesions in organ transplant recipients. A clinicopathologic and virologic assessment. Arch Dermatol 1997; 133: 175–178.
- 10. Biomarkers in screening of cervical cancer. In: MonsonegoJ, ed. Emerging Issues on HPV Infections: From Science to Practice. Basel , Karger, 2006: 1–19.
- 11, , , , , . Human papillomavirus infection and cervical intraepithelial neoplasia in women with renal allografts. BMJ 1989; 298: 153–156.
- 12, , . Anal cancer in renal transplant patients. Int J Colorectal Dis 2007; 22: 1–5.
- 13, , , . Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: A meta-analysis. Lancet 2007; 370: 59–67.
- 14. Post-transplant malignancy: The role of immunosuppression. Drug Saf 2000; 23: 101–113.
- 15, , et al. Human papillomavirus infection in nonmelanoma skin cancer in immunosuppressed and immunocompetent individuals. J Med Virol 2000; 61: 289–297.
- 16, , . Skin cancers after organ transplantation. N Engl J Med 2003; 348: 1681–1691.
- 17, . Update on the pathogenesis of post-transplant skin cancer in renal transplant recipients. Br J Dermatol 2008; 158: 217–224.
- 18, , et al. Ten years of sirolimus therapy for human renal transplantation: The University of Texas at Houston experience. Transplant Proc 2003; 35(Suppl 3): 25S–34S.
- 19, , et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007; 356: 1944–1956.
- 20, . Recurrent respiratory papillomatosis. Arch Dis Child 2006; 91: 689–691.
- 21, , , , . European guideline for the management of anogenital warts. Int J STD AIDS 2001; 12(Suppl 3): 40–47.
- 22
- 23, . Centers for Disease Control and Prevention Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006; 55(RR-11): 1–94.
- 24American Colllege of Obstetricians and Gynecologists. ACOG Committee Opinion No.431, May 2009: Routine Pelvic Examination and Cervical cytology screening. Obstet Gynecol 2009; 113: 1190–1193.
- 25, , et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002; 52: 342.
- 26, , . Diagnostic problems in anal pathology. Adv Anat Pathol 2008; 15: 263–278.
- 27, , et al. Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: A nested case-control study. Lancet 2000; 355: 2189–2193.
- 28, , et al. Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: A nested case-control study. Lancet 2000; 355: 2194–2198.
- 29, . Genital human papillomavirus infection. Clin Infect Dis 2006; 43: 624–629.
- 30, , , , , . Viral warts in organ transplant recipients: New aspects in therapy. Br J Dermatol 2003; 149(Suppl 66): 20–24.
- 31, , , British Association of Dermatologists. Guidelines for the management of cutaneous warts. Br J Dermatol 2001; 144: 4–11.
- 32, , et al. Conversion to sirolimus: A useful strategy for recalcitrant cutaneous viral warts in liver transplant recipient. Liver Transpl 2006; 12: 1883–1887.
- 33, , , , , , Centers for Disease Control and Prevention (CDC), National Institutes of Health, HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58(RR-4): 1–207.
- 34
- 35. Clinical Dermatology, 4th Ed. Philadelphia , Mosby, 2004.
- 36. Papillomavirus and treatment. Antiviral Res 2006; 71: 181–191.
- 37, , et al. Safety and efficacy of 0.5% podofilox gel in the treatment of anogenital warts. Arch Dermatol 1998; 134: 33–38.
- 38Graceway Pharmaceuticals. Aldara Prescribing Information. http://www.aldara.com/ie/pdfs/aldara_ppi.pdf. Accessed August 8, 2009.
- 39, , et al. Topical retinoids for warts and keratoses in transplant recipients. Lancet 1992; 340: 48–49.
- 40, , . Squamous cell carcinoma in situ (Bowens Disease) in renal transplant patients treated with 5% imiquimod and 5% 5-fluorouracil therapy. Dermatol Surg 2001; 27: 561–564.
- 41, . Use of topical immunomodulators in organ transplant recipients. Dermatol Ther 2005; 18: 19–27.Direct Link:
- 42, , , , , . Imiquimod cream 5% for recalcitrant cutaneous warts in immunosuppressed individuals. Br J Dermatol 2005; 152: 122–129.
- 43, , et al. 5% topical imiquimod tolerance in transplant recipients. Dermatology 2007; 215: 130–133.
- 44, , et al. Topical immunomodulation under systemic immunosuppression: Results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. Br J Dermatol 2007; 157(Suppl 2): 25–31.
- 45, , , . Skin cancers in transplant patients. Nephrol Dial Transplant 1998; 13: 1374–1379.
- 46, . Successful treatment of recalcitrant warts with topical squaric acid in immunosuppressed child. Pediatr Dermatol 2008; 25: 275–276.
- 47, , et al. Phase II double-blind, placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infection. Clin Infect Dis 2001; 33: 597–602.
- 48, , et al. Local administration of cidofovir for human papilloma virus associated skin lesions in transplant recipients. Transpl Int 2007; 20: 238–246.
- 49, , , , . Refractory human papillomavirus-associated oral warts treated topically with 1–3% cidofovir solutions in human immunodeficiency virus type 1-infected patients. Br J Dermatol 2005; 152: 590–591.
- 50, , et al. Topical use of cidofovir induced acute renal failure. Transplantation 2002; 73: 661–662.
- 51, , , , , . 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 2007; 197: 346–355.
- 52, , et al. International Transplant-Skin Cancer Collaborative; European Skin Care in Organ Transplant Patients Network. Guidelines for the management of squamous cell carcinoma in organ transplant recipients. Dermatol Surg 2004; 30(4 Pt 2): 642–650.
- 53, , , . Skin cancer in organ transplant recipients—where do we stand today? Am J Transplant 2008; 8: 2192–2198.
- 54. Human papilloma virus—Prevention and treatment. Obstet Gynecol Clin N Am 2008; 35: 199–217.
- 55, , , , , . Human papillomaviruses in transplant-associated skin cancers. Dermatol Surg 2004; 30: 604–609.
- 56. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: A combined analysis of four randomised clinical trials. Lancet 2007; 369: 1861–1868.
- 57, , et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347: 1645–1651.
- 58, , et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial. Lancet 2004; 364: 1757–1765.
- 59, , et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial. Lancet 2006; 367: 1247–1255.
- 60, , et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: A randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 271–278.
- 61, , et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006; 95: 1459–1466.
- 62, , et al. Substantial impact on precancerous lesions and HPV infections through 5.5 years in women vaccinated with the HPV-16/18 L1 VLP AS04 candidate vaccine [abstract] #4900. Annual American Association for Cancer Research Meeting, Los Angeles , CA : April 14–18, 2007.
- 63, , et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356: 1928–1943.
- 64The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 1915–1927.
- 65, , , , , . Quadrivalent human papillomavirus vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56(RR-2): 1–24.
- 66, , et al. Safety and immunogenity of a quadrivalent vaccine to prevent human papilloma virus infection in HIV-infected children: IMPAACT P1047 [abstract #619a]. Presented at the annual meeting of Conference on Retroviruses and Opportunistic Infections, February 3–6, 2008, Boston , Massachusetts .
- 67, , et al. A randomized, placebo-controlled, dose-escalation study to determine the safety, tolerability, and immunogenicity of an HPV-16 therapeutic vaccine in HIV-positive participants with oncogenic HPV infection of the anus. J Acquir Immune Defic Syndr 2009 Aug 5 [Epub ahead of print]
- 68, . Update on immunizations in solid organ transplant recipients: What clinicians need to know. Am J Transplant 2008; 8: 9–14.
- 69, , , . Influenza vaccination does not promote cellular or humoral activation among heart transplant recipients. Transplantation 2000; 69: 2449–2451.
- 70, , , , . Influenza vaccination in orthotopic liver transplant recipients: Absence of post administration ALT elevation. Am J Transplant 2004; 4: 1805–1809.
- 71, , . Model for assessing human paillomavirus vaccination strategies. Emerg Infect Dis 2007; 13: 28–41.
- 72U.S. Preventive Services Task Force recommendations on screening for cervical cancer. Release date: January 2003. http://www.ahrq.gov/clinic/USpstf/uspscerv.htm. Accessed on August 20, 2009.